Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Annji Pharmaceutical Co's Enterprise Value is NT$5,747.14 Mil.
Annji Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-354.02 Mil. Therefore, Annji Pharmaceutical Co's EV-to-FCF for today is -16.23.
The historical rank and industry rank for Annji Pharmaceutical Co's EV-to-FCF or its related term are showing as below:
ROCO:7754'
s EV-to-FCF Range Over the Past 10 Years
Min: -44.07 Med: -15.74 Max: -4.36
Current: -17.26
During the past 5 years, the highest EV-to-FCF of Annji Pharmaceutical Co was -4.36. The lowest was -44.07. And the median was -15.74.
ROCO:7754's EV-to-FCF is ranked worse than 100% of 334
companies
in the Biotechnology industry
Industry Median: 15.69
vs ROCO:7754: -17.26
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Annji Pharmaceutical Co (ROCO:7754) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Annji Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Annji Pharmaceutical Co's share price for today is NT$59.90.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Annji Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-3.781.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7754 vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, Annji Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Annji Pharmaceutical Co EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Annji Pharmaceutical Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Annji Pharmaceutical Co's EV-to-FCF falls into.
Annji Pharmaceutical Co's current Enterprise Value is NT$5,747.14 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Annji Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-354.02 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Annji Pharmaceutical Co (ROCO:7754) has a EV-to-FCF of -16.23 as of Jul. 16, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Annji Pharmaceutical Co and its competitors. According to the industry distribution chart, Annji Pharmaceutical Co ranks #999999 out of 334 companies in the Biotechnology industry.
Is Annji Pharmaceutical Co's EV-to-FCF too high?
Annji Pharmaceutical Co's current EV-to-FCF is -16.23. Based on the distribution chart, Annji Pharmaceutical Co ranks #999999 out of 334 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Annji Pharmaceutical Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Annji Pharmaceutical Co's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Annji Pharmaceutical Co ranks #999999 out of 334 companies for EV-to-FCF. This places Annji Pharmaceutical Co in the lower half of its industry. The industry median EV-to-FCF is 15.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.69, based on 334 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Annji Pharmaceutical Co and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Annji Pharmaceutical Co's current EV-to-FCF is -16.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Annji Pharmaceutical Co stock overvalued right now?
Annji Pharmaceutical Co (ROCO:7754) has a current EV-to-FCF of -16.23. The current EV-to-FCF is -16.23. Annji Pharmaceutical Co's overall GF Score™ is 9/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Annji Pharmaceutical Co (ROCO:7754), the current EV-to-FCF is -16.23 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Annji Pharmaceutical Co Ltd is an R&D based, clinical-stage new drug company dedicated to the development of first-in-class small molecules focusing on indications with highly unmet needs in the therapeutic areas of neurology, dermatology, and inflammatory disorders, including rare diseases such as idiopathic pulmonary fibrosis and Kennedy's disease, or SBMA (Spinal and bulbar muscular atrophy). Its pipeline products include AJ201, AJ302 and AJ303.
9GF Score
Get the complete analysis for ROCO:7754
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7754 has been successfully added to your 
